Dr. Reddy's Laboratories (RDY) said Thursday it has a licensing agreement with Shanghai Henlius Biotech for HLX15, an investigational daratumumab biosimilar to treat multiple myeloma.
The agreement grants Dr. Reddy's exclusive commercialization rights for both subcutaneous and intravenous formulations of HLX15 in the US and Europe, the company said.
Henlius will manage development, manufacturing and supply, potentially earning up to $131.6 million, including a $33 million upfront payment, milestone payments, and royalties on net annual sales of the product.
HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and is being developed as a biosimilar of Darzalex and Darzalex Faspro, manufactured by Janssen Biotech, a subsidiary of Johnson & Johnson.
Dr. Reddy shares rose 0.1% in recent Thursday trading, and Johnson & Johnson fell 0.5%.
Price: 13.99, Change: +0.01, Percent Change: +0.11
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。